Hedge Fund Stock Picks & Ticker Coverage
Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Sequoia Fund Arman Gökgöl-Kline, John Harris, Trevor Magyar | “Align Technology, Inc. (“Align”) is the company behind the Invisalign clear aligner orthodontic system. After years of rapid growth, the business has stagnated since 2021 due to post-pandemic normalization, weaker dental traffic, and increased competition following patent expirations. Despite these headwinds, Align remains the clear global leader with a comprehensive orthodontic ecosystem spanning software, manufacturing, logistics, and brand demand. Clear aligners remain structurally underpenetrated globally across both adult and teen markets. We purchased shares at a low-to-mid-teens multiple of forward earnings, which we believe reflects overly pessimistic assumptions about long-term growth and competitive erosion. BSD Analysis: Align Technology is focused on a recovery narrative for 2026, with analysts projecting an 11% upside as the dental market stabilizes. The company maintains an industry-leading 64% gross margin and continues to innovate within its Invisalign system to address more complex skeletal corrections. While EPS growth has seen historical volatility, the expansion of digital dentistry and the "Smiles4Canada" program highlight its long-term brand-building efforts. Management is preparing to announce fiscal results that Wall Street expects will show renewed earnings momentum and improved operating margins. Despite a high P/E ratio, the company's role as the dominant innovator in clear aligner therapy provides a significant barrier to entry for lower-cost competitors. Investors are keeping a close watch on consumer discretionary spending as the primary determinant for the pace of Align's 2026 expansion.” | BULL | Q4 2025 Jan 30, 2026 | View Pitch |
Giverny Capital Asset Management David M. Poppe | “Align Technology struggled in 2025 as orthodontic demand softened amid consumer pressure and increased competition at the low end of the market. Despite these headwinds, Invisalign remains the premium standard in clear aligners, supported by strong brand recognition, superior clinical outcomes, and deep relationships with orthodontists. Management continues to invest in product innovation, digital workflows, and international expansion, which we believe will reignite growth as consumer demand normalizes. We remain confident in Align's long-term earnings power and market leadership. BSD Analysis: Align is orthodontics monetized through workflow dominance, not just Invisalign trays. Digital scanning, software, and dentist training lock practitioners into the ecosystem. Demand is cyclical, but orthodontics doesn't disappear — it defers and then snaps back. Investors fixate on competition and miss how hard it is to replicate Align's end-to-end system. Margins flex with volume, but scale advantages persist. International penetration remains underdeveloped relative to brand strength. This is medical devices behaving like a platform, not a single product.” | BULL | Q4 2025 Oct 24, 2025 | View Pitch |
Meridian Growth Fund ArrowMark Colorado Holdings, LLC | “Align Technology, Inc. is a global leader in dental technology and the maker of Invisalign clear aligners. We were initially drawn to Align for its strong competitive position and innovative iTero digital scanning system, which enables clinicians to design more precise treatment plans and enhances the overall patient experience. The stock underperformed during the quarter as expectations for a demand rebound did not materialize. Patient conversion rates softened, most notably within the teen segment, where revenue growth slowed to 3%. In addition, market share gains reversed amid a weaker macroeconomic backdrop for discretionary dental procedures and a shift toward lower-cost wires and brackets. Given these dynamics, we trimmed our position during the period. :contentReference[oaicite:12]{index=12} BSD Analysis: ALGN faces cyclical and competitive headwinds; mix shift to lower-cost alternatives pressures pricing. Longer-term, digital adoption persists, but near-term volume softness argues for caution. Watchteen demand, international mix, and ASP stabilization as triggers.” | BEAR | Q3 2025 Sep 30, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.